Fintel reports that on April 14, 2023,
Needham
maintained
coverage of Merus N.V. (NASDAQ:MRUS) with
a Buy recommendation.
Analyst Price Forecast Suggests 76.80% Upside
As of April 7, 2023,
the average one-year price target for Merus N.V. is $38.45.
The forecasts range from a low of $33.33 to a high of $49.35.
The average price target represents an increase of 76.80% from its latest reported closing price of $21.75.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Merus N.V.
is $41MM, a decrease of 0.83%.
The projected annual non-GAAP EPS
is -$3.45.
What are Other Shareholders Doing?
China Universal Asset Management Co.
holds 0K shares
representing 0.00% ownership of the company.
In it’s prior filing, the firm reported owning 0K shares, representing
an increase
of 8.92%.
The firm
decreased
its portfolio allocation in MRUS by 99.93% over the last quarter.
Alps Advisors
holds 31K shares
representing 0.07% ownership of the company.
In it’s prior filing, the firm reported owning 25K shares, representing
an increase
of 20.28%.
The firm
decreased
its portfolio allocation in MRUS by 9.44% over the last quarter.
Schonfeld Strategic Advisors
holds 45K shares
representing 0.10% ownership of the company.
In it’s prior filing, the firm reported owning 130K shares, representing
a decrease
of 187.46%.
The firm
decreased
its portfolio allocation in MRUS by 73.28% over the last quarter.
Millennium Management
holds 341K shares
representing 0.74% ownership of the company.
In it’s prior filing, the firm reported owning 529K shares, representing
a decrease
of 55.36%.
The firm
increased
its portfolio allocation in MRUS by 10,010.23% over the last quarter.
FBIOX – Biotechnology Portfolio
holds 459K shares
representing 0.99% ownership of the company.
In it’s prior filing, the firm reported owning 630K shares, representing
a decrease
of 37.45%.
The firm
decreased
its portfolio allocation in MRUS by 53.97% over the last quarter.
What is the Fund Sentiment?
There are 153 funds or institutions reporting positions in Merus N.V..
This is an increase
of
5
owner(s) or 3.38% in the last quarter.
Average portfolio weight of all funds dedicated to MRUS is 0.40%,
a decrease
of 32.92%.
Total shares owned by institutions increased
in the last three months by 8.86% to 39,389K shares.
The put/call ratio of MRUS is 0.08, indicating a
bullish
outlook.
Merus N.V Background Information
(This description is provided by the company.)
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.
See all Merus N.V. regulatory filings.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
